OTCMKTS:IPSEY - IPSEN S A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$33.19 -1.16 (-3.38 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$33.19
Today's Range$33.19 - $33.48
52-Week Range$30.43 - $44.60
Volume840 shs
Average Volume1,600 shs
Market Capitalization$11.11 billion
P/E Ratio19.07
Dividend Yield0.64%
Beta0.66
Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPSEY
CUSIPN/A
CIKN/A
Phone33-01-58-33-50-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 billion
Cash Flow$2.1221 per share
Book Value$6.50 per share

Profitability

Miscellaneous

Employees5,401
Market Cap$11.11 billion
Next Earnings DateN/A
OptionableNot Optionable

IPSEN S A/S (OTCMKTS:IPSEY) Frequently Asked Questions

What is IPSEN S A/S's stock symbol?

IPSEN S A/S trades on the OTCMKTS under the ticker symbol "IPSEY."

What is the consensus analysts' recommendation for IPSEN S A/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IPSEN S A/S in the last year. There are currently 2 sell ratings and 1 hold rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for IPSEN S A/S.

Has IPSEN S A/S been receiving favorable news coverage?

News coverage about IPSEY stock has been trending positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IPSEN S A/S earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the immediate future.

Who are some of IPSEN S A/S's key competitors?

What other stocks do shareholders of IPSEN S A/S own?

Who are IPSEN S A/S's key executives?

IPSEN S A/S's management team includes the folowing people:
  • Mr. David D. Meek, CEO & Director (Age 56)
  • Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 50)
  • Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 53)
  • Dr. Alexandre P. Lebeaut, Exec. VP of R&D and Chief Scientific Officer (Age 62)
  • Ms. Eugenia Litz, VP of Investor Relations

How do I buy shares of IPSEN S A/S?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IPSEN S A/S's stock price today?

One share of IPSEY stock can currently be purchased for approximately $33.19.

How big of a company is IPSEN S A/S?

IPSEN S A/S has a market capitalization of $11.11 billion and generates $2.76 billion in revenue each year. The company earns $460 million in net income (profit) each year or $1.74 on an earnings per share basis. IPSEN S A/S employs 5,401 workers across the globe.

What is IPSEN S A/S's official website?

The official website for IPSEN S A/S is http://www.ipsen.com.

How can I contact IPSEN S A/S?

IPSEN S A/S's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]


MarketBeat Community Rating for IPSEN S A/S (OTCMKTS IPSEY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about IPSEN S A/S and other stocks. Vote "Outperform" if you believe IPSEY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPSEY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel